Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 138Carcinoma, Non-Small-Cell Lung 109Prostatic Neoplasms 51Lung Neoplasms 31Neoplasm Metastasis 20Stomach Neoplasms 18Parkinson Disease 4, Autosomal Dominant Lewy Body 17Nasopharyngeal Carcinoma 16Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Esophageal Neoplasms 11Head and Neck Neoplasms 8Urinary Bladder Neoplasms 7HER2-positive Breast Cancer 7Esophageal Squamous Cell Carcinoma 7Ovarian Neoplasms 6Carcinoma 6Adenocarcinoma 6Inflammatory Breast Neoplasms 5Fallopian Tube Neoplasms 5Endometrial Neoplasms 5Carcinoma, Squamous Cell 5Adenocarcinoma of Lung 5Triple Negative Breast Neoplasms 4Recurrence 4Carcinoma, Transitional Cell 4Adenocarcinoma Of Esophagus 4Primary Breast Cancer 3Carcinoma, Ovarian Epithelial 3Adenocarcinoma, Bronchiolo-Alveolar 3

Interventions

spartalizumab 1sintilimab 1Nivolumab 1Docetaxel 1Carboplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Squamous Cell Non-small Cell Lung Cancer × Docetaxel × Clear all
NCT01642004 2022-12-28

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)

Bristol-Myers Squibb

Phase 3 Completed
272 enrolled 23 charts
Thoracic

Squamous Cell Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡